Journal of Emergencies, Trauma, and Shock
Home About us Editors Ahead of Print Current Issue Archives Search Instructions Subscribe Advertise Login 
Users online:32   Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size   


 
INTERDISCIPLINARY FOCUS Table of Contents   
Year : 2008  |  Volume : 1  |  Issue : 2  |  Page : 106-113
Mucormycosis in immunochallenged patients


1 University of South Florida College of Medicine, 12901 Bruce B. Downs Blvd., Tampa, Florida 33612, Division of Infectious Diseases and International Medicine, Department of Internal Medicine, College of Medicine, University of South Florida, 12901 Bruce B. Downs Blvd., Tampa, Florida 33612-4742, USA
2 University of South Florida College of Medicine, 12901 Bruce B. Downs Blvd., Tampa, Florida 33612, Department of Medicine, Division of Infectious Tropical Diseases, H. Lee Moffitt Cancer Center and Research Institute; Associate Professor of Pathology and Interdisciplinary Oncology, University of South Florida College of Medicine, 12902 Magnolia Drive, Tampa, Florida 33612-9497, USA

Click here for correspondence address and email
 

   Abstract 

Mucorales species are deadly opportunistic fungi with a rapidly invasive nature. A rare disease, mucormycosis is most commonly reported in patients with diabetes mellitus, because the favorable carbohydrate-rich environment allows the Mucorales fungi to flourish, especially in the setting of ketoacidosis. However, case reports over the past 20 years show that a growing number of cases of mucormycosis are occurring during treatment following bone marrow transplants (BMT) and hematological malignancies (HM) such as leukemia and lymphoma. This is due to the prolonged treatment of these patients with steroids and immunosuppressive agents. Liposomal amphotericin B treatment and posaconazole are two pharmacologic agents that seem to be effective against mucormycosis, but the inherently rapid onset and course of the disease, in conjunction with the difficulty in correctly identifying it, hinder prompt institution of appropriate antifungal therapy. This review of the literature discusses the clinical presentation, diagnosis, and treatment of mucormycosis among the BMT and HM populations.

Keywords: Fungal infections, Mucorales, mucormycosis

How to cite this article:
Pak J, Tucci VT, Vincent AL, Sandin RL, Greene JN. Mucormycosis in immunochallenged patients. J Emerg Trauma Shock 2008;1:106-13

How to cite this URL:
Pak J, Tucci VT, Vincent AL, Sandin RL, Greene JN. Mucormycosis in immunochallenged patients. J Emerg Trauma Shock [serial online] 2008 [cited 2019 Nov 13];1:106-13. Available from: http://www.onlinejets.org/text.asp?2008/1/2/106/42203


Mucormycosis is a rare and rapidly progressive opportunistic fungal infection that most often presents among patients with diabetes mellitus, immunodeficiency, neutropenia, iron overload, and severe burns. There has been a reported rise in mucormycosis among patients with hematological malignancies (HM), e.g., acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), and in bone marrow transplant (BMT) recipients due to the neutropenia and immunodeficiency associated with chemotherapy and post-transplant steroid treatment. [1],[2],[3] Due to the difficulty in early diagnosis and the especially detrimental course in leukemia and BMT patients, there is an urgent need to develop new methods for the rapid diagnosis and treatment of this disease.

Though a relatively uncommon fungal infection in comparison with candidiasis and aspergillosis, mucormycosis cases have been on the rise over the past decade. [4] One study indicates that the increase is due to the the increased use of chemotherapy and steroids, which is associated with a prolonged immunocompromised state. [5] Mucormycosis can be caused by any fungal species within the Mucorales order. This mold infection is also referred to as zygomycosis or phycomycosis in the literature. The most commonly seen genera in mucormycosis cases are Rhizopus , Rhizomucor , Mucor , and Absidia . [6],[7] Mucormycosis is unique among the filamentous fungi because of its capacity to cause disease in a much wider human population than the other opportunistic fungi.


   Etiology Top


Mucorales, first described in 1885 by Paltauf, [8] is the largest and most widely studied order of the fungal class Zygomycete. The most commonly seen genera in mucormycosis are from the Mucoraceae family; recently, however, an increasing number of Cunninghamella infections from the Cunninghamellaceae family are also being reported. [Figure 1] shows the classification of the clinically relevant families, genera, and species of the Mucorales order.

Mucorales fungi are characterized by fast-growing fibrous mycelium and thin-walled aseptate or hyposeptate hyphae that measure 10-20 µm in width. Right-angled branching is also seen as it rapidly grows within the host tissue. As the hyphae grow they invade the blood vessels and result in tissue infarction. [7],[9] This ultimately leads to tissue necrosis and vessel thrombosis. [7],[10]

Although it is an uncommon infection in the general population, exposure to Mucorales is common. Most species are saprotrophic, obtaining their nutrients from dead organic matter, and grow in soil, fruit, bread, and plants. Some are characterized as parasites of animals, plants, and other fungi. Mucormycosis infection in humans is usually acquired through airborne fungal spores. [7],[10] The number of spores rapidly increases in carbohydrate-rich environments. Increased availability of soluble iron in the host is also believed to play a role in promoting Mucorales growth, especially in patients receiving deferoxamine iron chelation therapy, where the deferoxamine acts as a siderophore so the fungi may utilize the iron in its growth. [11],[12],[13]

For optimal growth in humans, Mucorales fungi require the host to have decreased levels of neutrophils. Neutrophils are the key defense against the fungi in the host tissue. In healthy humans with intact immune systems, neutrophils phagocytize these pathogens. However, in neutropenic individuals, the unregulated pathogens proliferate in the host tissue and infection ensues. Neutropenia is often a side effect of chemotherapy in cancer patients or of the malignancy itself and is also seen in immunocompromised individuals. The vast majority of patients with mucormycosis are neutropenic, with neutrophil counts usually below 0.5 × 10 9 /l. The reference range is 1.8 × 10 9 /l to 7 × 10 9 /l.


   Epidemiology Top


The literature reports an increase in mucormycosis, as compared to invasive aspergillosis, among immunocompromised patients over the last 2 decades. [14] Marr et al. , based on their study of 5589 transplant patients at the Fred Hutchinson Cancer Center, report that the number of cases of mucormycosis have more than doubled from 1985-1989 to 1995-1999. [1] Rhizopus are the most commonly isolated species among these patients. Less common, but increasingly frequent in the general population, is the Cunninghamella bertholletiae species. [15],[16] No studies have indicated any bias for or against any specific gender, race, or age.

According to one study, the annual incidence of mucormycosis in the general population is 1.7 cases for every 1 million individuals, which amounts to approximately 500 affected Americans each year. [17] However, this is likely to be an underestimate because of the low rate (23-50%) of antemortem diagnosis [18] and also because a large number of cases remain undiagnosed due to the decline in autopsies in the United States and Europe from around 60% in the 1960s to around 10% at present. [19],[20],[21] Although most cases of mucormycosis are seen in patients with unregulated diabetes mellitus, the numbers have been decreasing over the past 20 years and, instead, an increasing numbers of individuals with HM are presenting with the infection. Recent studies indicate that 1-3% of BMT patients present with mucormycosis. [10],[22],[23] The incidence of mucormycosis in adult leukemia patients is reported at around 2%. [24] Those leukemia patients who have developed neutropenia due to chemotherapy or the malignancy are most susceptible to the fungus. Mortality rates in patients with HM who have mucormycosis is greater than 50%. [3],[25]

[Table 1] details several case reports culled from PubMed on June 16, 2007, reporting individual occurrences of mucormycosis in BMT and HM patients. Of the 34 cases presented, 10 patients (29.4%) survived the infection with successful treatment, 19 patients (55.9%) died due to ineffective treatment of the infection, and the remaining 5 (14.7%) died due to other infections or disease processes (though autopsy showed that the Mucorales infection had been successfully eradicated). These high mortality figures are similar to those reported by Kara et al. in a 5-year (2001-2005) retrospective study of 20 HM patients admitted to the Medical Oncology Division at the Cukurova University Hospital in Turkey [25] ; the authors reported a mortality rate of 55% and a successful treatment rate of 40% in their series. [25]


   Clinical Presentation Top


Mucormycosis commonly presents in five forms: it may affect the pulmonary, rhinocerebral, gastrointestinal, cutaneous, or the central nervous systems. [7] Dissemination may also occur due to the highly invasive nature of Mucorales. [7] Dissemination is a term used to describe an infection that affects two or more noncontiguous organ systems. Of the five forms, pulmonary and rhinocerebral are the most common. Disseminated mucormycosis affects the lungs and brain most often, with the infection usually originating in the lungs. [6] Our review of the case reports in the literature suggest that among HM and BMT patients the pulmonary presentation of mucormycosis is most common, followed by the disseminated form. A study by Lee et al. of 87 pulmonary mucormycosis patients indicated that those with HM comprised 32% of the cases; the majority (56%) of the cases were those with diabetes mellitus. [5] [Table 2] details the different features associated with each of the five forms of the infection and the common differential diagnoses for each.

The most common symptom in pulmonary mucormycosis is a high-grade fever (> 39°C) that does not subside despite the administration of antibiotics. [5],[16],[24],[26],[32],[36],[42],[43],[44],[45],[46],[47] Coughing and respiratory distress are also seen. Auscultation of these patients' chests may reveal moist rales and pleural friction rubs. Pleuritic chest pain is often present in these patients. Oral thrush may also appear. Computed tomography of the chest may show ill-defined round densities, halo and lobar expansion, and pleural infiltrates. Patchy consolidations and cavitations may also be seen on chest radiography.

Cases of rhinocerebral mucormycosis present with facial pain, periorbital cellulitis, proptosis, visual deficiencies, black necrotic lesions and discharge from the nasal and palatal mucosa, and fever. [38],[48],[49] Biopsy reveals fungal hyposeptated hyphae consistent with Mucorales. Most patients with this form of mucormycosis have diabetes mellitus [5] ; it is not very common among BMT and HM patients.

Gastrointestinal mucormycosis presents with features similar to that seen in bowel obstruction. Tenderness on palpation, with or without the presence of a mass, and hepatomegaly or splenomegaly have been reported. [23],[34] This form of the infection is seen most commonly among malnourished adults and in individuals with underlying gastrointestinal disease or abnormalities such as kwashiorkor, colitis, typhoid, or pellagra. [2]

Cutaneous involvement by mucormycosis has been reported as presenting with black necrotic lesions, most often on the face and extremities. Many of the cases of cutaneous mucormycosis reported in BMT and HM patients seem to have been caused by A corymbifera . The site of the lesion may be where catheters are placed. [40] Reports in the literature suggest that due to the superficial nature of these infections, early diagnosis and surgical debridement with skin grafting give highly favorable outcomes. [23],[30],[33],[40]

Brain mucormycosis is not common by itself; CNS involvement is usually a result of dissemination of the fungal infection from pulmonary or rhinocerebral sources. [37] Paterson et al. have reported a CML patient in whom mucormycosis spread through the ear to invade cerebral tissue; the patient died 15 days post-BMT. [35]


   Diagnosis Top


Mucormycosis can be a fatal infection and early diagnosis and treatment are of extreme importance for successful eradication of the infection and for patient survival. Differential diagnoses may be varied due to the different clinical presentations and organ systems involved. The most commonly employed technique for differentiating between mucormycosis and other diseases is a histopathological study. [50] However, due to the frequently encountered difficulty in distinguishing Mucorales from other filamentous fungi, [9] more sophisticated diagnostic techniques are emerging and being evaluated. A discussion of the various techniques available follows. [Table 3] summarizes their general features, issues, and efficacy.

For a definitive diagnosis of mucormycosis, the histopathological specimen need not be of the isolated fungus, but may be a sample of the necrotic tissue from the site in question. The Grocott-Gomori methenamine silver (GMS) stain is most effective for identifying fungi. However, hematoxylin and eosin, periodic acid-Schiff (PAS), or Calcofluor White stains may also be used. [2] Invasion of the tissue by fungal hyphae and right-angle branching will be present in mucormycosis specimens. [9] Fungal angioinvasion, perineural invasion, and the presence of neutrophilic infiltrate in the necrotic tissue are also characteristic of mucormycosis. [9] Mucorales are sometimes difficult to distinguish in tissues from other filamentous fungi on histopathological examination. [9] Nevertheless, histopathology continues to be commonly employed for the diagnosis of mucormycosis.

Culture studies often fail to grow Mucorales in mucormycosis patients. Blood cultures are especially known to produce false negative results. The ideal culturing technique is to receive the infarcted tissue and submit it for processing by mincing the tissue with a sterile scalpel and not by grinding it. The syncytial cells of the Mucorales fail to grow in culture if submitted to a grinding procedure, which will produce small fragments devoid of any enclosing septal cell walls. Mucorales grow well on Sabouraud dextrose, brain-heart infusion, or potato dextrose agar incubated at 25-30°C. Identification of saprophytic mold does not conclusively indicate that an infection with that organism has occurred; therefore culture is not usually used alone for diagnosis.

A recent Mayo clinic study using the MicroSeq D2 large-subunit ribosomal DNA sequencing kit to identify filamentous fungi concluded that nucleic acid sequencing using this technique holds much promise, with accurate identification possible in under 24 h. [51] However, more work needs to be done to improve its relevance to the more clinically prevalent fungal species. Less than 50% of the Zygomycetes tested in this study were identified correctly. Kobayashi et al. recently conducted a study showing the usefulness of panfungal PCR on serial serum samples for diagnosing pulmonary mucormycosis caused by Cunninghamella bertholletiae . [45] Rickerts et al. reported the use of a combination of two nested PCR assays to differentiate between Aspergillus and Zygomycetes (which are difficult to tell apart by clinical and radiographic signs) and successfully identified the Zygomycetes to the species or genus level. [52] They were able to identify the organism in culture-negative samples as well. Another technique that has been recently developed takes advantage of the sequence variability in the internal transcribed spacer 2 (ITS2) of fungi for identifying Zygomycete isolates to the species level; this is possible because of the significantly different sequences between species. [53],[54]

At present, serological testing is not recommended for diagnosis due to its investigational status. [55] Only a few reported cases have used antibody testing for mucor IgE in order to diagnose mucormycosis. [56]

Susceptibility testing is used to determine a drug's potential effectiveness for eradicating infection and inhibiting growth of the pathogen. One susceptibility testing method commonly used for Aspergillus utilizes fluorescence-based microplate assays. This method may come into use for Zygomycetes in the future but has not yet been comprehensively evaluated. A recent study by Antachopoulos showed that clinically important Zygomycetes show significant metabolic activity in XTT assays even before visual or spectrophotometric evidence of activity becomes apparent. [57] XTT is the tetrazolium salt 2,3-bis{2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide}. The XTT assay is a colorimetric method of quantifying fungal growth by measuring the metabolism of XTT by fungal mitochondrial dehydrogenases. Electron transfer agents such as menadione are also needed for efficient reduction. [57] These XTT assays, performed at 6-12 h post-inoculation, provided results in agreement with the older standard methods of susceptibility testing, which are done 24 h post-inoculation. Several other methods exist for rapid susceptibility testing in filamentous fungi, however many are purely for assessing susceptibility to amphotericin B and require the use of expensive laboratory equipment or potentially hazardous substances. In contrast, XTT assays may also be used for testing susceptibility to other drugs and is a more viable alternative for use in most laboratories.


   Treatment Top


Mortality rates among patients with HM who have mucormycosis remain high despite antifungal therapy. Surgical intervention and debridement is the gold standard of treatment for eradicating the infection. [4],[7],[58] However many of the clinical presentations do not allow for such methods of treatment. Favored alternatives for treatment include various amphotericin B formulations and posaconazole, with different Mucorales genera and species showing slight differences in susceptibilities to the drugs. [59] Most cases that have been successfully treated have required approximately 5 weeks of therapy.

There are many similarities in the clinical presentations of aspergillosis and mucormycosis. The ineffectiveness of the drugs used in aspergillosis for the treatment of mucormycosis makes it especially important to establish the diagnoses as early as possible in the course of disease. For leukemia and BMT patients who receive prophylactic antifungal drugs as part of their treatment, it is crucial to distinguish between the different fungal infections as soon as possible after symptoms appear in order to administer the correct antifungal therapy. Early correction of predisposing factors such as neutropenia and immunodeficiency are also important in controlling the progression of the infection.

The most effective treatments for mucormycosis in BMT and leukemia patients are various formulations of amphotericin B combined with posaconazole. [59] Itraconazole is somewhat ineffective against Mucorales, especially against Rhizopus species. [6],[59] there is conflicting data on the efficacy of echinocandins against mucormycosis and the reported cases do not present a strong argument either way. [60],[61]

Voriconazole, an effective drug in aspergillosis, [62] is not recommended against mucormycosis due to its ineffectiveness both in vitro and in vivo . [22],[46],[59],[63],[64],[65] Not only is voriconazole ineffective in the treatment of mucormycosis, it has also been associated with breakthrough infections of mucormycosis. [22],[63],[64],[66] Several cases have been published where patients with HM were given voriconazole against Aspergillus infection, only to find that they develop mucormycosis later. These cases showed breakthrough mucormycosis at 9-12 days after voriconazole administration was started as an empiric antifungal treatment in leukemia. Marty et al. also reports breakthrough mucormycosis in stem cell transplant recipients who received voriconazole as prophylactic or empiric therapy. [22] Voriconazole is an effective drug against Aspergillus , Candida , Scedosporium , and Fusarium . [67],[68] The popular utilization of this drug for prophylaxis against common fungal agents allows the Mucorales (which are resistant to it) to emerge unchallenged and infect these highly immunocompromised patients. [66] These findings emphasize the need for more caution when using voriconazole as a prophylactic agent in this patient population.

Amphotericin B has been the drug of choice against mucormycosis for over 50 years due to its superior effectiveness compared to other therapies. Treatment duration is usually between 3 and 6 weeks and the total dose that needs to be administered ranges from 2.0-4.0 g, depending on the specific case. [7] Among the different formulations of this drug are liposomal amphotericin B (LAmB) and cochleate-containing amphotericin B (CAmB). LAmB is relatively low in toxicity and does not have many adverse effects, making it the favored choice. Salonen described one leukemia patient in whom LAmB therapy was concurrently administered with chemotherapy. [26] An allogeneic bone marrow transplantation had been done in this patient and it was possible to prevent relapses of mucormycosis throughout the treatment period by continuing LAmB in conjunction with secondary antifungal prophylaxis. According to Wingard et al. , administration of CAmB to treat mucormycosis may not be favorable and may even be toxic due to the high dosage levels and prolonged treatment required. [69] Another lipid formulation of amphotericin B, amphotericin B lipid complex (ABLC), has had success in treating patients with mucormycosis.

Posaconazole is a relatively new drug that appears to be a promising alternative or adjunctive to LAmB administration. [59],[70],[71] Rickerts et al. reported the case of a leukemia patient in whom disseminated mucormycosis was successfully treated with the use of a combination of LAmB and posaconazole without surgical intervention. Other authors have also reported similar success. [62],[72] Many experienced conditions favor combination therapy of posaconazole and lipid formulations of amphotericin B over monotherapy. However, there is no conclusive data yet available to determine if combination therapy is additive, synergistic, or antagonistic.

Another alternative or adjuvant therapy is hyperbaric oxygen (HBO). A study published in 2004 by Garcia-Covarrubias showed 60% survival rate using HBO as an adjuvant therapy to amphotericin B and surgical debridement. [73] A 1994 study of 208 cases by Yohai also supported the improvement in prognosis with the use of HBO. [74] Despite its promising outlook, the literature is still too sparse in this area to make a conclusive case for including HBO as part of the treatment regimen.


   Conclusion Top


The high mortality rate among mucormycosis patients calls for an increased index of suspicion and aggressive attempts to diagnose and treat the disease at an early stage. Because of its rarity, mucormycosis is often not included in the differential diagnosis until widespread Mucorales invasion has already taken place in the patient. Its commonplace presence in the environment emphasizes the importance of keeping the wards and hospital instruments free of these opportunistic fungi. Increasing the implementation of promising new diagnostic methods such as PCR nested assays and ITS2 sequencing may help increase the rate of successful Mucorales identification in the early stages of infection. However, the new assays await FDA approval for implementation in hospital-based clinical microbiology laboratories. LAmB and posaconazole treatment have helped to treat many cases of mucormycosis. However, despite these advances, the incidence of the infection has risen in recent years, in part due to the use of prolonged chemotherapy and immunosuppressive treatment in HM and BMT patients. Given the increase in cases of breakthrough mucormycosis after general antifungal prophylaxis and the overall increase in cases in this population, anti-Mucorales prophylaxis studies are warranted and should be given due importance, alongside the search for better methods of diagnosis and treatment.[75]

 
   References Top

1.Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-17.  Back to cited text no. 1    
2.Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000;13:236-301.  Back to cited text no. 2    
3.Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis 2005;41:634-53.  Back to cited text no. 3    
4.Pagano L, Offidani M, Fianchi L, Nosari A, Candoni A, Piccardi M, et al. Mucormycosis in hematologic patients. Haematologica 2004;89:207-214  Back to cited text no. 4    
5.Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: The last 30 years. Arch Intern Med 1999;159:1301-9.  Back to cited text no. 5    
6.Groves C, Saltz J. Johns Hopkins Microbiology Newsletter, Baltimore: 1996. Available from: http://pathology5.pathology.jhmi.edu/micro/v15n33.htm. [cited on 2007 Jun 5].   Back to cited text no. 6    
7.Sugar AM. Mucormycosis. Clin Infect Dis 1992;14:5126-9.  Back to cited text no. 7    
8.Paltauf A. Mycosis mucorina. Arch Pathol Anat 1885;102:543-64.  Back to cited text no. 8    
9.Frater JL, Hall GS, Procop GW. Histologic features of zygomycosis: Emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med 2001;125:375-8.  Back to cited text no. 9    
10.Morrison VA, McGlave PB. Mucormycosis in the BMT population. Bone Marrow Transplant 1993;11:383-8.  Back to cited text no. 10    
11.Boelaert JR, de Locht M, Van Cutsem J, Kerrels V, Cantinieaux B, Verdonck A, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993;91:1979-86.  Back to cited text no. 11    
12.Ibrahim AS, Edwards JE, Fu Y, Spellberg B. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother 2006;58:1070-3.  Back to cited text no. 12    
13.Reed C, Ibrahim A, Edwards JE, Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006;50:3968-9.  Back to cited text no. 13    
14.Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymph 2004;45:1351-60.  Back to cited text no. 14    
15.Kontoyianis DP, Vartivarian S, Anaissie EJ, Samonis G, Bodey GP, Rinaldi M. Infections due to Cunninghamella bertholletiae in patients with cancer: Report of three cases and review. Clin Infect Dis 1994;18:925-8.  Back to cited text no. 15    
16.Rickerts V, B φhme A, Viertel A, Behrendt G, Jacobi V, Tintelnot K, et al. Cluster of pulmonary infections caused by Cunninghamella bertholletiae in immunocompromised patients. Clin Infect Dis 2000;31:910-3.  Back to cited text no. 16    
17.Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: Results of population-based laboratory active surveillance. Clin Infect Dis 1998;27:1138-47.  Back to cited text no. 17    
18.Nosari A, Oreste P, Montillo M, Carrafiello G, Draisci M, Muti G, et al. Mucormycosis in hematologic malignancies: An emerging fungal infection. Haematologica 2000;85:1068-71.  Back to cited text no. 18    
19.Welsh TS, Kaplan J. The role of postmortem examination in medical education. Mayo Clin Proc 1998;73:802-5.  Back to cited text no. 19    
20.Burton JL, Underwood J. Clinical, educational, and epidemiological value of autopsy. Lancet 2007;369:1471-80.  Back to cited text no. 20    
21.Roulson J, Benbow EW, Hasleton PS. Discrepancies between clinical and autopsy diagnosis and the value of post mortem histology: A meta-analysis and review. Histopathology 2005;47:551-9.  Back to cited text no. 21    
22.Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004;350:950-2.  Back to cited text no. 22    
23.Maertens J, Demuynck H, Verbeken EK, Zachιe P, Verhoef GE, Vandenberghe P, et al. Mucormycosis in allogeneic bone marrow transplant recipients: Report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 1999;24:307-12.  Back to cited text no. 23    
24.Funada H, Matsuda T. Pulmonary mucormycosis in a hematology ward. Intern Med 1996;35:540-4.  Back to cited text no. 24    
25.Kara IO, Tasova Y, Uguz A, Sahin B. Mucormycosis-associated fungal infections in patients with haematologic malignancies. Int J Clin Pract 2007; [Epub ahead of print].  Back to cited text no. 25    
26.Salonen JH. Successful management of cerebral and pulmonary mucormycosis with liposomal amphotericin B in a 28-year-old woman with acute lymphoblastic leukemia. Acta Biomed 2006;77:28-31.  Back to cited text no. 26    
27.Saito T, Ikezoe T, Daibata M, Takeuchi T, Ohtsuki Y, Taguchi H, Miyoshi I. Disseminated mucormycosis (zygomycosis) in acute myeloid leukemia. Intern Med 2006;45:1073-4.  Back to cited text no. 27    
28.Bethge WA, Schmalzing M, Stuhler G, Schumacher U, Kr φber SM, Horger M, et al. Mucormycoses in patients with hematologic malignancies: An emerging fungal infection. Haematologica 2005;90:ECR22  Back to cited text no. 28    
29.Barron MA, Lay M, Madinger NE. Surgery and treatment with high-dose liposomal amphotericin B for eradication of craniofacial zygomycosis in a patient with Hodgkin's disease who had undergone allogeneic hematopoietic stem cell transplantation. J Clin Microbiol 2005;43:2012-4.  Back to cited text no. 29    
30.Cloughley R, Kelehan J, Corbett-Feeney G, Murray M, Callaghan J, Regan P, et al. Soft tissue infection with Absidia corymbifera in a patient with idiopathic aplastic anemia. J Clin Microbiol 2002;40:725-7.  Back to cited text no. 30    
31.Lee DG, Choi JH, Choi SM, Yoo JH, Kim YJ, Min CK, et al. Two cases of disseminated mucormycosis in patients following allogeneic bone marrow transplantation. J Korean Med Sci 2002;17:403-6.  Back to cited text no. 31    
32.Maddox L, Long GD, Vredenburgh JJ, Folz RJ. Rhizopus presenting as an endobronchial obstruction following bone marrow transplant. Bone Marrow Transplant 2001;28:634-6.  Back to cited text no. 32    
33.Hadithi M, Leemans CR, Jonkhoff AR. Tge irreplaceable image: Cutaneous mucormycosis in acute myeloid leukemia; hit hard and quickly. Haematologica 2001;86:1320.  Back to cited text no. 33    
34.Suh IW, Park CS, Lee MS, Lee JH, Chang MS, Woo JH, et al. Hepatic and small bowel mucormycosis after chemotherapy in a patient with acute lymphocytic leukemia. J Korean Med Sci 2000;15:351-4.  Back to cited text no. 34    
35.Paterson PJ, Marshall SR, Shaw B, Kendra JR, Ethel M, Kibbler CC, et al. Fatal invasive cerebral Absidia corymbifera infection following bone marrow transplantation. Bone Marrow Transplant 2000;26:701-3.  Back to cited text no. 35    
36.Leleu X, Sendid B, Fruit J, Sarre H, Wattel E, Rose C, et al. Combined anti-fungal therapy and surgical resection as treatment of pulmonary zygomycosis in allogeneic bone marrow transplantation. Bone Marrow Transplant 1999;24:417-20.  Back to cited text no. 36    
37.Birchall D, Leong WK, McAuliffe W. Cerebral mucormycosis. JJ Neurol Neurosurg Psychiatry 1999;66:404-5.  Back to cited text no. 37    
38.Peρalver FJ, Romero R, Fores R, Cabrera R, Diez-Martin JL, Regidor C, et al. Rhinocerebral mucormycosis following donor leukocyte infusion: Successful treatment with liposomal amphotericin B and surgical debridement. Bone Marrow Transplant 1998;22:817-8.  Back to cited text no. 38    
39.Jantunen E, Kolho E, Ruutu P, Koukila-Kδhk φlδ P, Virolainen M, Juvonen E, et al. Invasive cutaneous mucormycosis caused by Absidia corymbifera after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996;18:229-30.  Back to cited text no. 39    
40.Leong KW, Crowley B, White B, Crotty GM, O'Briain DS, Keane C, et al. Cutaneous mucormycosis due to Absidia corymbifera occurring after bone marrow transplantation. Bone Marrow Transplant 1997;19:513-5.  Back to cited text no. 40    
41.Benbow EW, Delamore IW, Stoddart RW, Reid H. Disseminated zygomycosis associated with erythroleukaemia: Confirmation by lectin stains. J Clin Pathol 1985;38:1039-44.  Back to cited text no. 41    
42.al-Abbadi MA, Russo K, Wilkinson EJ. Pulmonary mucormycosis diagnosed by bronchoalveolar lavage: A case report and review of the literature. Pediatr Pulmonol 1997;23:222-5.  Back to cited text no. 42    
43.Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005;41:60-6.  Back to cited text no. 43    
44.Funada H, Miyake Y, Kanamori K, Okafuji K, Machi T, Matsuda T. Fluconazole therapy for pulmonary mucormycosis complicating acute leukemia. Jpn J Med 1989;28:228-31.  Back to cited text no. 44    
45.Kobayashi M, Togitani K, Machida H, Uemura Y, Ohtsuki Y, Taguchi H. Molecular polymerase chain reaction diagnosis of pulmonary mucormycosis caused by Cunninghamella bertholletiae. Respirology 2004;9:397-401.  Back to cited text no. 45    
46.Mattner F, Weissbrodt H, Strueber M. Two case reports: Fatal Absidia corymbifera pulmonary tract infection in the first postoperative phase of a lung transplant patient receiving voriconazole prophylaxis, and transient bronchial Absidia corymbifera colonization in a lung transplant patient. Scand J Infect Dis 2004;36:312-4.  Back to cited text no. 46    
47.Tricot S, Gastine T, Sendid B, Wurtz A, de Botton S, Alfandari S. Pulmonary zygomycosis in a patient treated for invasive aspergillosis [Article in French]. Med Mal Infect 2006;36:118-21.  Back to cited text no. 47    
48.Jayachandran S, Krithikia C. Mucormycosis presenting as palatal perforation. Indian J Dent Res 2006;17:139-42.  Back to cited text no. 48  [PUBMED]  Medknow Journal
49.Khor BS, Lee MH, Leu HS, Liu JW. Rhinocerebral mucormycosis in Taiwan. J Microbiol Immunol Infect 2003;36:266-9.  Back to cited text no. 49    
50.Carvalhal GF, Machado MG, Pompeo A, Saldanha L, Sabbaga E, Arap S. Mucormycosis presenting as a renal mass in a patient with the human immunodeficiency virus. J Urol 1997;158:2230-1.  Back to cited text no. 50    
51.Hall L, Wohlfiel S, Roberts GD. Experience with the MicroSeq D2 large-subunit ribosomal DNA sequencing kit for identification of filamentous fungi encountered in the clinical laboratory. J Clin Microbiol 2004;42:622-6.  Back to cited text no. 51    
52.Rickerts V, Just-Nubling G, Konrad F, Kern J, Lambrecht E, B φhme A, et al. Diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients by seminested PCR assay of tissue samples. Eur J Clin Microbiol Infect Dis 2006;25:8-13.  Back to cited text no. 52    
53.Turenne CY, Sanche SE, Hoban DJ, Karlowsky JA, Kabani AM. Rapid identification of fungi by using the ITS2 genetic region and an automated fluorescent capillary electrophoresis system. J Clin Microbiol 1999;37:1846-51.  Back to cited text no. 53    
54.Schwarz P, Bretagne S, Gantier JC, Garcia-Hermoso D, Lortholary O, Dromer F, et al. Molecular identification of zygomycetes from culture and experimentally infected tissues. J Clin Microbiol 2006;44:340-9.  Back to cited text no. 54    
55.Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: Pathophysiology, presentation, and management. Clin Microbiol Rev 2005;18:556-69.  Back to cited text no. 55    
56.Wysong DR, Waldorf AR. Electrophoretic and immunoblot analyses of Rhizopus arrhizus antigens. J Clin Microbiol 1987;25:358-63.  Back to cited text no. 56    
57.Antachopoulos C, Meletiadis J, Roilides E, Sein T, Walsh TJ. Rapid susceptibility testing of medically important zygomycetes by XTT assay. J Clin Microbiol 2006;44:553-60.  Back to cited text no. 57    
58.Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: A review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004;10:31-47.  Back to cited text no. 58    
59.Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE, Eurofung Network In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003;51:45-52.  Back to cited text no. 59    
60.Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998;36:2950-6.  Back to cited text no. 60    
61.Jacobs P, Wood L, Du Toit A, Esterhuizen K. Eradication of invasive mucormycosis--effectiveness of the Echinocandin FK463. Hematology 2003;8:119-23.  Back to cited text no. 61    
62.Petrikkos G, Skiada A. Recent advances in antifungal chemotherapy. Int J Antimicrob Agents 2007;30:108-17.  Back to cited text no. 62    
63.Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004;39:743-6.  Back to cited text no. 63    
64.Oren I. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis 2005;40:770-1.  Back to cited text no. 64    
65.Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, Bartelt LA, Kilborn SB, Hoth PL, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004;39:584-7.  Back to cited text no. 65    
66.Vigouroux S, Morin O, Moreau P, Mιchinaud F, Morineau N, Mahι B, et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: Attention required. Clin Infect Dis 2005;40:e35-7.  Back to cited text no. 66    
67.Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998;42:741-5.  Back to cited text no. 67    
68.Johnson LB, Kauffman CA. Voriconazole: A new triazole antifungal agent. Clin Infect Dis 2003;36:630-7.  Back to cited text no. 68    
69.Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:1402-7.  Back to cited text no. 69    
70.Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006;50:126-33.  Back to cited text no. 70    
71.Dannaoui E, Meis JF, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother 2003;47:3647-50.  Back to cited text no. 71    
72.Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: A broad-spectrum triazole antifungal. Lancet Infect Dis 2005;5:775-85.  Back to cited text no. 72    
73.Garcνa-Covarrubias L, Barratt DM, Bartlett R, Van Meter K. Treatment of mucormycosis with adjunctive hyperbaric oxygen: Five cases treated at the same institution and review of the literature] [Article in Spanish]. Rev Invest Clin 2004;56:51-5.  Back to cited text no. 73    
74.Yohai RA, Bullock JD, Aziz AA, Markert RJ. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophtalmol 1994;39:3-22  Back to cited text no. 74    
75.Zygomycetes. Gainesville: University of Florida Herbarium; 2006. Available from: http://zygomycetes.org. [cited on 2007 Jun 10].  Back to cited text no. 75    

Top
Correspondence Address:
John N Greene
University of South Florida College of Medicine, 12901 Bruce B. Downs Blvd., Tampa, Florida 33612, Department of Medicine, Division of Infectious Tropical Diseases, H. Lee Moffitt Cancer Center and Research Institute; Associate Professor of Pathology and Interdisciplinary Oncology, University of South Florida College of Medicine, 12902 Magnolia Drive, Tampa, Florida 33612-9497
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0974-2700.42203

Rights and Permissions


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1], [Table 2], [Table 3]

This article has been cited by
1 Rhinomucormycosis and type 1 diabetes mellitus
Katty Manrique,Cristina Martín,Olga Sánchez-Vilar,Carmen Aragón,Alicia Cazorla,Adela Rovira
Endocrinología y Nutrición (English Edition). 2013; 60(3): 149
[Pubmed] | [DOI]
2 Rinomucormicosis y diabetes mellitus tipo 1
Katty Manrique,Cristina Martín,Olga Sánchez-Vilar,Carmen Aragón,Alicia Cazorla,Adela Rovira
Endocrinología y Nutrición. 2013; 60(3): 149
[Pubmed] | [DOI]
3 Pulmonary mucormycosis presenting with vocal cord paralysis
H.J. Gayathri Devi,K.N. Mohan Rao,K.M. Prathima,Riyaz Moideen
Respiratory Medicine Case Reports. 2013; 9: 15
[Pubmed] | [DOI]
4 Rhinocerebral mucormycosis due to Rhizopus oryzae in a diabetic patient: A case report
M. Erami,M. Shams-Ghahfarokhi,Z. Jahanshiri,A. Sharif,M. Razzaghi-Abyaneh
Journal de Mycologie Médicale / Journal of Medical Mycology. 2013; 23(2): 123
[Pubmed] | [DOI]
5 Rhino-oculo Cerebral Mucormycosis with Multiple Cranial Nerve Palsy in Diabetic Patient: Review of Six Cases
Kavita Sachdeva
Indian Journal of Otolaryngology and Head & Neck Surgery. 2013;
[Pubmed] | [DOI]
6 Cutaneous Rhizopus infection at a central venous catheter site in a critically ill renal transplant patient
Zoel A. Quiñónez,John T. Speicher,Christian Sebat,Mark Avdalovic
Healthcare Infection. 2012; 17(3): 83
[Pubmed] | [DOI]
7 Rhinocerebral mucormycosis—a case report
Shaji Thomas, V. Dal Singh, Yuvaraj Vaithilingam, Sumeeth Cyriac Thayil, Rohit Kothari
Oral and Maxillofacial Surgery. 2011;
[VIEW] | [DOI]
8 Verlaufsbeobachtung einer rhinozerebralen Zygomykose bei einem nur teilweise complianten Patienten
I. Gruber, B. Lackinger
Spektrum der Augenheilkunde. 2010; 24(3): 162
[VIEW] | [DOI]
9 Rhinocerebralis zygomycosisból gyógyult diabeteses férfi esete
Botond Lakatos, Radka Nikolova, László Ocskay, Judit Csomor, Gyula Prinz
Orvosi Hetilap. 2010; 151(39): 1591
[VIEW] | [DOI]



 

Top
 
  Search
 
  
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
    Treatment
    Etiology
    Epidemiology
    Clinical Present...
    Diagnosis
    Treatment
    Conclusion
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed7636    
    Printed283    
    Emailed4    
    PDF Downloaded240    
    Comments [Add]    
    Cited by others 9    

Recommend this journal